A canadian open-label access program to evaluate the safety and the effectiveness of adalimumab when added to inadequate therapy for the treatment of psoriasis.

Trial Profile

A canadian open-label access program to evaluate the safety and the effectiveness of adalimumab when added to inadequate therapy for the treatment of psoriasis.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2010

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms PRIDE
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 30 May 2010 Quality-of-life results and effects on depression presented at the 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 16 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top